BEAD BIOPHARMA LIMITED
🌿Early-stageactive
SC763273 · ltd · incorporated 2023-03-22
Investment thesis
Growth-phase business — story-led; valuation sensitive to momentum.
Why interesting: Trading is scaling; acquirers paying for trajectory get disproportionate leverage.
Why risky: Price often leads fundamentals; dependency on founder often high.
🔒Estimated value
—
Upgrade to see
Turnover
—
year to Mar 2025
Net worth
£483.4k
book net assets
Opportunity
75/100
Strong
What this business does
Primary activity: Research and experimental development on biotechnology
Sector: Professional, scientific & technical
Investor take
PursueStrong opportunity: asset-holding vehicle with strong profile and acceptable with review structure.
Opportunity 75/100 (strong), bankability 70/100. Share purchase looks the cleaner deal structure. Most likely exit: share sale to pe / searcher (65/100).
Data confidence
Overall: high (80/100)Strong data coverage across all sections. AI outputs should be trusted with minimal caveats.
Company profile
address, 1 SIC codes, incorporation date
100
Financials
2 years of iXBRL accounts extracted (YoY deltas available) + narrative notes parsed
75
Lenders & charges
Confirmed no charges registered
85
Directors & officers
7 officers (5 active, 7 linked, 7 with DOB)
90
Ownership & PSC
1 active PSC(s) of 1 total, 1 with control declared
90
Director network
4 connected companies via shared directors
57
Filing history
23 filings on record
85
Gazette notices
No matching gazette notices (standard for active companies)
60
Opportunity Score
75/100Strong
PassWatchWorth a lookStrongExceptional
Solid opportunity signal. Worth a dedicated memo and management meeting.
Business quality
60
Adequate — check latest filings for context.
Acquirability
70
Strong succession / seller-readiness signals.
Risk profile
85
Few red flags.
Signal strength
90
Good data coverage for analysis.
Signals from accounts
Derived from iXBRL accounts · accounting standard not declaredPositive net assets
Net assets £483,398
Key financials
2 years extracted from filed iXBRL accountsCash
£460k
Net Worth
£483k
↑ 1296% YoY
Current Assets
£534k
Current Liabilities
—
Hover to see exact values · click legend to toggle series
Financials
Extracted from Companies House accounts · accounting standard unknown| Metric | 2025-03-31 | 2024-03-31 |
|---|---|---|
| Total assets | £483.7k | £-40.4k |
| Current assets | £534.1k | — |
| Cash | £459.6k | — |
| Debtors | £66.9k | £4.9k |
| Net assets | £483.4k | £-40.4k |
Amounts extracted automatically from iXBRL. Fields left blank were not reported or not mapped. Values in GBP unless stated.
🔒Filing-note intelligence
1 signal detected in this company's narrative notes — going-concern language, audit opinion, contingent liabilities, related-party transactions.
Available from the Pro tier upwards.
See pricing →Recent activity
Last 30 days
1
filing
- • 1 address
Last 90 days
2
filings
- • 1 address
- • 1 confirmation-statement
Last 180 days
4
filings
- • 1 address
- • 1 confirmation-statement
- • 1 officers
Counts from Companies House filing history.
Corporate timeline (30 events)Click to expand
- 2026-04-07📍change-registered-office-address-company-with-date-old-address-new-addressaddress · AD01
- 2025-12-05📄appoint-person-director-company-with-name-dateofficers · AP01
- 2025-12-01➕OZANNE, Daniel Matthew, Dr appointeddirector
- 2025-11-10📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2025-10-27📄memorandum-articlesincorporation · MA
- 2025-10-27📄resolutionresolution · RESOLUTIONS
- 2025-10-27📄capital-allotment-sharescapital · SH01
- 2025-10-27📄change-to-a-person-with-significant-controlpersons-with-significant-control · PSC04
- 2025-06-27📄change-to-a-person-with-significant-controlpersons-with-significant-control · PSC04
- 2024-10-31➖OZANNE, Daniel, Dr resigneddirector
- 2024-10-31📄termination-director-company-with-name-termination-dateofficers · TM01
- 2024-10-18📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2024-04-19➕OZANNE, Daniel, Dr appointeddirector
- 2024-04-19📄appoint-person-director-company-with-name-dateofficers · AP01
- 2024-04-08📄capital-alter-shares-subdivisioncapital · SH02
- 2024-04-03📄memorandum-articlesincorporation · MA
- 2024-04-03📄resolutionresolution · RESOLUTIONS
- 2024-04-02➕SUN, Michael appointeddirector
- 2024-04-02📄appoint-person-director-company-with-name-dateofficers · AP01
- 2024-04-02📄capital-allotment-sharescapital · SH01
- 2023-12-15📍change-registered-office-address-company-with-date-old-address-new-addressaddress · AD01
- 2023-11-03📍change-registered-office-address-company-with-date-old-address-new-addressaddress · AD01
- 2023-07-17📄termination-director-company-with-name-termination-dateofficers · TM01
- 2023-07-11➖RAYMOND, Alan Michael, Dr resigneddirector
- 2023-03-22🏢Company incorporatedAs BEAD BIOPHARMA LIMITED
- 2023-03-22➕BROWN, Stephen, Dr appointeddirector
- 2023-03-22➕CLEMENTS, Richard John appointeddirector
- 2023-03-22➕MOODY, David John, Dr appointeddirector
- 2023-03-22➕RAYMOND, Alan Michael, Dr appointeddirector
- 2023-03-22📄incorporation-companyincorporation · NEWINC
Owner dependency
55/100
Moderate — manageable with handoverSome founder dependency, but not acute. A structured handover period should cover most risk.
FACTORS
- -5 active directors: Broader management team in place — suggests transferable governance.
- +Founder age: Director aged approximately 68 — succession pressure is live.
Succession & seller-readiness
50/100
Moderate signalSome succession indicators present. Worth watching; approach if sector/strategy fits.
SIGNALS
- primaryFounder aged 63+: Senior director is approximately 68. Approaching typical UK retirement age — succession thinking likely.
Red flags
cleanNo red flags detected from available public data. (This is not a clean bill of health — detailed accounts review still recommended.)
Shareholders & ownership
1 active beneficial owner| Name | Shares | Voting rights | Nature of control | Notified |
|---|---|---|---|---|
Dr David John Moody Individual · British · DOB 11/1959 · age 67 | 25–50% | 25–50% | 25-50% shares · 25-50% voting | 22/03/2023 |
From Companies House Persons with Significant Control filings. Share ranges are banded per the public PSC regime.
🔒Co-director network graph
Radial SVG graph showing every company connected via shared directors, colour-coded by status.
Available from the Pro tier upwards.
See pricing →Similar companies
Active · Professional services · AB postcode area| Company | Est. value | Turnover | Net worth | Staff | Age | Opp | Director |
|---|---|---|---|---|---|---|---|
| C R C SERVICES SCOTLAND LTD→ SC791666 · est 2023 · no financials extracted | — | — | — | — | 2y | — | — |
| C-SUBSEA LIMITED→ SC499649 · est 2015 · no financials extracted | — | — | — | — | 11y | — | — |
| C. THOW LTD→ SC654238 · est 2020 · no financials extracted | — | — | — | — | 6y | — | — |
| CORESTRUCT CONSULT LIMITED→ SC383899 · est 2010 · no financials extracted | — | — | — | — | 15y | — | — |
| CORROSION ASSOCIATES LIMITED→ SC201702 · est 1999 · no financials extracted | — | — | — | — | 26y | — | — |
| COSTAIN UPSTREAM LIMITED→ SC336371 · est 2008 · no financials extracted | — | — | — | — | 18y | — | — |
| COUNTAX SERVICES LIMITED→ SC556566 · est 2017 · no financials extracted | — | — | — | — | 9y | — | — |
| CPM (INVERURIE) LTD→ SC556861 · est 2017 · no financials extracted | — | — | — | — | 9y | — | — |
| CRAIGIAN LIMITED→ SC161694 · est 1995 · no financials extracted | — | — | — | — | 30y | — | — |
| CREEGAN COMMUNICATIONS LTD→ SC712936 · est 2021 · no financials extracted | — | — | — | — | 4y | — | — |
| CREMIN ENGINEERING LTD→ SC613399 · est 2018 · no financials extracted | — | — | — | — | 7y | — | — |
| CRESCENT ENGINEERING SERVICES LTD→ SC765983 · est 2023 · no financials extracted | — | — | — | — | 3y | — | — |
Peers ranked by estimated value, then turnover, then opportunity score.See all →
🔒Tailored diligence questions
8 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →🔒Advanced scoring suite
Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Statusactive
Typeltd
Incorporated2023-03-22
Jurisdictionscotland
Primary SIC72110 — Research and experimental development on biotechnology
Registered office
Ormsary Cottage
Oyne
Insch
AB52 6QT
Scotland
Filing status
Accounts
Next due: 2026-12-31
Last made up to: 2025-03-31
Confirmation statement
Next due: 2027-04-04
Last: 2026-03-21
Officers (5 active · 2 resigned)
BROWN, Stephen, Dr→
Activedirector · ~68y · appointed 2023-03-22
View their other companies + combined net worth →
CLEMENTS, Richard John→
Activedirector · ~57y · appointed 2023-03-22
View their other companies + combined net worth →
MOODY, David John, Dr→
Activedirector · ~67y · appointed 2023-03-22
View their other companies + combined net worth →
OZANNE, Daniel Matthew, Dr→
Activedirector · ~50y · appointed 2025-12-01
View their other companies + combined net worth →
SUN, Michael→
Activedirector · ~55y · appointed 2024-04-02
View their other companies + combined net worth →
OZANNE, Daniel, Dr→
Resigneddirector · ~50y · appointed 2024-04-19 · resigned 2024-10-31
RAYMOND, Alan Michael, Dr→
Resigneddirector · ~73y · appointed 2023-03-22 · resigned 2023-07-11
Click a director name to see their full track record across all companies.
Recent filings (23 total)
change-registered-office-address-company-with-date-old-address-new-address
address · AD01
2026-04-07
confirmation-statement-with-updates
confirmation-statement · CS01
2026-03-23
appoint-person-director-company-with-name-date
officers · AP01
2025-12-05
accounts-with-accounts-type-total-exemption-full
accounts · AA
2025-11-10
memorandum-articles
incorporation · MA
2025-10-27
resolution
resolution · RESOLUTIONS
2025-10-27
capital-allotment-shares
capital · SH01
2025-10-27
change-to-a-person-with-significant-control
persons-with-significant-control · PSC04
2025-10-27
change-to-a-person-with-significant-control
persons-with-significant-control · PSC04
2025-06-27
confirmation-statement-with-updates
confirmation-statement · CS01
2025-03-21
termination-director-company-with-name-termination-date
officers · TM01
2024-10-31
accounts-with-accounts-type-total-exemption-full
accounts · AA
2024-10-18
appoint-person-director-company-with-name-date
officers · AP01
2024-04-19
capital-alter-shares-subdivision
capital · SH02
2024-04-08
memorandum-articles
incorporation · MA
2024-04-03